The new fluorinated 4-quinolone temafloxacin was compared with cefoxitin, clindamycin, imipenem (with or without cilastatin) and ampicillin/sulbactam in a mouse subcutaneous abscess model of Bacteroides fragitis infection. Based upon in-vitro susceptibility data, temafloxacin may represent an effective oral and parenteral alternative to standard oral and parenteral anti-anaerobic agents currently in use. Temafloxacin therapy with dosage regimens of < 200 mg/kg/day typically yielded 2-3 x log, 0 reductions in cfu/abscess, similar to ampicillin/sulbactam, while cefoxitin and clindamycin were generally unable to produce similar reductions at doses up to 400 mg/kg/day. Imipenem (with or without cilastatin) was unable to produce a 1 x log, 0 reduction at doses of 400 mg/kg/day. This study suggests that temafloxacin has potential for the treatment of anaerobic or mixed aerobic-anaerobic infections in man.
Introduction
Fluoroquinolones currently available are not active against most anaerobic species (Debbia et al, 1987; Klietmann, Focht & Nosner, 1987; Bellido & Pechere, 1989; Hoban, 1989; Nani et al., 1989) , although the first fluoroquinolones developed exhibited some activity against anaerobes, to the extent that certain strains were classified as susceptible, including various species of Clostridium, Capnocytophaga and Mobiluncus (Bellido & Pechere, 1989) . In-vitro synergy has been demonstrated between ciprofloxacin and non-quinolone anti-anaerobic agents against various strains representing the six major genera of anaerobes (Whiting Cheng & Chow, 1987) , and ciprofloxacin has shown activity against oral anaerobic flora (Wade, 1989) .
The newer fluoroquinolones with lower MICs for Gram-positive bacteria often possess enhanced in-vitro activity against anaerobes. These compounds include temafloxacin, sparfloxacin, WIN 57273, tosufloxacin, A-56620 and difloxacin (Hardy et al., 1987; Chin et al., 1988; Barry & Jones, 1989; Kojima, Inoue & Mitsuhashi, 1989; Eliopoulos, Klimm & Grayson, 1990; Jones & Barry, 1990; Nakanishi et al., 1990) . In animal models of intra-abdominal Bacteroides fragilis abscesses, tosufloxacin was more active than ciprofloxacin or metronidazole (Sesnie et al., 1989) , A-56620 was as effective as cefoxitin (Thadepalli, Gollapudi & Chuah, 1986) , and the activity of difloxacin was similar to that of the combination of clindamycin plus gentamicin (Thadepalli et al., 1986) . Killing kinetics and MICs of temafloxacin suggest that this drug would be active against anaerobes in the clinical situation, considering its J. Alder and J. J. Clement pharmacokinetic profile in man (Hardy et al., 1987; Chin et al., 1988; Barry & Jones, 1989; Nakanishi et al., 1990) .
The objective of this study was to compare the activity of the new fluoroquinolone temafloxacin with that of cefoxitin, clindamycin, imipenem (with or without cilastatin) and ampicillin/sulbactam in a subcutaneous abscess model in mice of B.fragilis infection. This study was undertaken to help assess the potential of temafloxacin as an alternative to standard anti-anaerobic agents in an in-vivo model. Standards, 1990) . The MICs of temafloxacin, cefoxitin, imipenem, clindamycin and ampicillin/sulbactam for this strain were 10, 80, 012, 050, and 10 mg/L, respectively. The strain was cultured on anaerobic blood agar and in thioglycolate broth with vitamin K and haemin (Difco Laboratories, Detroit, MI, USA) at 35°C. In-vitro antibacterial activity was determined on Wilkins-Chalgren agar (Difco Laboratories). An anaerobic chamber (Forma Scientific Anaerobe Chamber, Model 1025; Marietta, OH, USA) was used for isolation, culture and MIC determinations.
Materials and methods

Compounds
In-vivo activity
The compounds were tested for therapeutic activity in a subcutaneous B. fragilis-assodated mid-scapular region abscess infection model in 17-20 g CF1 (Sasco Inc, Omaha, NE, USA) mice, Experimental infections were initiated by subcutaneous injection of approximately 1 x 10 7 cfu of B.fragilis strain 1999 in sterilized 25% faecal material. The mouse faeces were sterilized by autoclaving. Study drugs were administered ip bd (at 1, 16, 28, 40, 52, 64, 76 , and 84 h post-infection). Dosage regimens utilized are illustrated in Tables I to V. Each treatment and control group consisted of ten mice. Therapy was based upon high doses of antibiotic delivered systemically by injection ip. Therapy was continued by injections bd for four days. This dosage scheme was determined to be effective in allowing reduction of bacterial counts in anaerobic lesions.
Representative replicate trials are presented in Tables I to IV . Abscesses were removed aseptically 1 h after the last dose administration, homogenized in 1 mL PBS, and viable counts determined for each abscess on 5% TSA blood agar plates (BBL, Cockeysville, MA, USA). The plates were incubated for 48 h under anaerobic conditions in anaerobe jars (GasPac; BBL). The minimum number of bacteria detectable by this method (100 cfu/abscess) was calculated with the Maximum Likelihood Estimate and its Asymptotic Standard Error technique (Rao, 1973) . Analysis of variance (ANOVA) analysis was conducted upon dose-response groups, and 95% confidence intervals were generated for effective dose 50% values (EDy,).
A pharmacokinetic study of all five compounds in serum and abscess was conducted in a separate trial. Groups of mice were inoculated with B.fragilis strain 1999 as before, and abscess formation was allowed to proceed for 96 h. A single dose of test compound was then administered ip. The doses utilized during this pharmacokinetic evaluation were as follows: temafloxacin and imipenem/cilastatin, 200 mg/kg; cefoxitin, clindamycin, and ampicillin/sulbactam, 400 mg/kg. Abscess tissue was removed, weighed and homogenized in PBS. The mean abscess mass was 0-453 g (±0-018 S.E.M.). Serum and abscess drug concentrations were determined before dosing, and 0-5, 1,2,3, 6, and 24 h following dosing. Five mice were used for each time point determination, with a total of 30 mice/drug.
At each time point, serum was collected and the abscesses were removed. The antibiotic concentrations in serum and abscess tissue were determined by an agar diffusion bioassay, procedure, with Klebsiella pneumoniae ATCC 10031 used as the assay organism for temafloxacin and ciprofloxacin, Staphylococcus aureus ATCC 6538 used for cefoxitin, and Micrococcus luteus ATCC 9341 used as the assay organism for clindamycin and ampicillin. The detection limits were 01 mg/L for temafloxacin, imipenem, clindamycin and ampicillin, and 120 mg/L for cefoxitin.
These trial protocols were reviewed and approved by the Abbott Animal Care and Use Committee.
Results
Tables I to FV illustrate the results of the four trials presented in the context of our study, while Table V depicts the single-dose serum and abscess pharmacokinetic parameters and MICs of the five study compounds.
Temafloxacin appeared to be superior to the other agents in reducing the burden of B.fragilis in this subcutaneous abscess infection model in mice. Treatment with temafloxacin at a dosage of < 200 mg/kg/day generally yielded 2-3 x log 10 reductions in cfu/abscess. Cefoxitin and clindamycin, in general, proved unable to produce 2-3 x log, 0 reductions in bacterial counts at doses up to 400 mg/kg/day. The ED^ to yield a 3 x log, 0 reduction in bacterial counts for there two compounds were > 400 mg/kg/day, compared with values of 122 and 185 mg/kg/day for temafloxacin (Tables I and II) . Temafloxacin was similar to activity to ampicillin/sulbactam, yielding respective 3 x log, 0 ED^s of 73 and 156 mg/kg in Trial 3, and 1 x log 10 EDJOS of 97 and > 400 mg/kg in Trial 4 (Tables III and IV) . Imipenem (with or without cilastatin) was unable to produce a 1 x log l0 reduction in bacterial counts at doses ranging from 200-400 mg/kg/day (Tables III and IV) .
A 200 mg/kg dose of temafloxacin yielded a serum AUC,^,, value of 129-8 mg/L.h, which was in excess of the values produced by a 200 mg/kg dose of imipenem/cilastin (5-5 mg/L.h) or 400 mg/kg doses of cefoxitin, clindamycin or ampicillin/sulbactam (15-3, 21 1 and 17-3 mg/L.h, respectively). Similarly, the abscess AUQ.^ value of temafloxacin (148-5 /ig/g.h) was in excess of the values produced by clindamycin, imipenem/cilastin or ampicillin/sulbactam (106-7, 11 and 20-9//g/g.h, respectively). Temafloxacin had the longest half-life in serum (2-67 h) and abscesses (4-73 h), which x log ]0 reductions in cfu/abscess 2 x log 10 94-4 (92-0-96-9)* >400 341-1(204-9-> 400)* 3 x log 10 122-2(118-8-125-6)* >400 >400 72-9 (62-9-84-4)* >200 155-6 (118-7-203-9)* 
I
Discussion
Previous in-vitro studies have reported excellent intrinsic activity of the fluoroquinolones against a wide spectrum of infectious agents (Cohen et al., 1985; Hooper & Wolfson, 1991) . The predictive value of this in-vitro activity for in-vivo efficacy can be affected by in-vivo interactions between the infecting organism, host, and antimicrobial agent. It is influenced by in-vivo drug absorption, distribution, metabolism, and excretion processes (Hinderling, 1978) . It is also affected by the state of host defences (Bodey, Feld & Burgess, 1976) and environmental factors present at the infection site (Bryant & Hammond, 1974; Zeiler, 1985) . Experimental local or systemic infection models are often used to evaluate the potential in-vivo efficacy of antimicrobial agents (Zeiler & Grohe, 1984; Heifetz et al., 1988) . Although there are some disadvantages and variability inherent in these screening models (Barza, 1978) , their predictive ability has, generally, been good (Miraglia, 1976; Bergeron, 1978) .
In our animal infection model evaluation, the fluoroquinolone temafloxacin exhibited substantial in-vivo activity against B. fragilis. Temafloxacin was superior to the standard antianaerobic agents cefoxitin, clindamycin and imipenem (with or without cilastatin), and comparable to ampicillin/sulbactam in reducing bacterial counts in abscesses. All effective compounds produced dose responsive ED,,, values. The dose increase required to produce log l0 increases in efficacy were smaller for temafloxacin than for the other agents. There was some variability in drug efficacy in the five trials. This was related to the inherent difficulty in establishing identical anaerobic abscesses in separate trials. These in-vivo results were in agreement with previous in-vitro findings obtained with temafloxacin (Hardy et al., 1987; Chin et al., 1988; Barry & Jones, 1989; Nakanishi et al., 1990) .
The present study also demonstrated the lack of correlation of MIC and efficacy data in the treatment of anaerobic abscesses. The two agents superior in efficacy (temafloxacin and ampicillin/sulbactam) had higher MICs than either imipenem or clindamycin. A potential reason for the superior results obtained with temafloxacin involved its advantageous pharmacokinetics, as outlined in Table V . Temafloxacin produced abscess AUC and 7^ values superior to those yielded by equal or larger doses of the other agents. This study supports the potential usefulness of the fluoroquinolone temafloxacin in the treatment of anaerobic and, based on previous work and aerobes, mixed anaerobic-aerobic infections. Consideration for temafloxacin treatment of intraabdominal and skin/skin structure infections is warranted.
